CSIMarket
 


Adc Therapeutics Sa  (ADCT)
Other Ticker:  
 
 

ADCT's Capital Expenditures Growth by Quarter and Year

Adc Therapeutics Sa's Capital Expenditures results by quarter and year




ADCT Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 3.22 0.00 0.00 0.00
III Quarter September 0.00 3.43 0.80 7.40
II Quarter June 0.00 0.00 0.00 6.70
I Quarter March 0.00 0.00 0.00 11.70
FY   3.22 3.43 0.80 25.80



ADCT Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Adc Therapeutics Sa in the fourth quarter 2023 achieved Capital Expenditures of $ 3.22 millions compare to Capital Expenditures recorded in same quarter a year ago.

Among companies who have reported fourth quarter 2023 results in the Major Pharmaceutical Preparations industry only one Company has achieved higher year on year Capital Expenditures results in the fourth quarter 2023. While Adc Therapeutics Sa' s Capital Expenditures no change of % ranks overall at the positon no. 20 in the fourth quarter 2023.




ADCT Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - 328.75 % -89.19 % -30.84 %
II Quarter June - - - -12.99 %
I Quarter March - - - 0.86 %
FY   -6.24 % 328.75 % -96.9 % -30.65 %

Financial Statements
Adc Therapeutics Sa's fourth quarter 2023 Capital Expenditures $ 3.22 millions ADCT's Income Statement
Adc Therapeutics Sa's fourth quarter 2022 Capital Expenditures $ 0.00 millions Quarterly ADCT's Income Statement
New: More ADCT's historic Capital Expenditures Growth >>


ADCT Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - 10.45 %
II Quarter June - - - -42.74 %
I Quarter March - - - 62.5 %
FY (Year on Year)   -6.24 % 328.75 % -96.9 % -30.65 %




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #3
Overall #20

Capital Expenditures Y/Y Growth Statistics
High Average Low
328.21 % -45.76 % -532.88 %
(Dec 31 2021)   (April 30, 2006)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #3
Overall #20
Capital Expenditures Y/Y Growth Statistics
High Average Low
328.21 % -45.76 % -532.88 %
(Dec 31 2021)   (April 30, 2006)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Adc Therapeutics Sa's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ADCT's IV. Quarter Q/Q Capital Expenditures Comment


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ADCT's IV. Quarter Q/Q Capital Expenditures Comment


Adc Therapeutics Sa's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
0
12 Months Ending
(Dec 31 2021)
12 Months Ending
0
Cumulative Capital Expenditures 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 3.43 $ 0.00
Y / Y Capital Expenditures Growth (TTM) - - - 328.21 % -
Year on Year Capital Expenditures Growth Overall Ranking # 20 # 1404 # 0 # 0 # 0
Seqeuential Capital Expenditures Change (TTM) - - - - -
Seq. Capital Expenditures Growth (TTM) Overall Ranking # # # # #




Cumulative Capital Expenditures growth Comment
In the Dec 31 2023 period, Adc Therapeutics Sa's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 20, from total ranking in previous quarter at 1404.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 0
Healthcare Sector # 3
Overall # 20

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
328.21 %
-45.76 %
-532.88 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Capital Expenditures growth Comment
In the Dec 31 2023 period, Adc Therapeutics Sa's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 20, from total ranking in previous quarter at 1404.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 0
Healthcare Sector # 3
Overall # 20

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
328.21 %
-45.76 %
-532.88 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
ADCT's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for ADCT's Competitors
Capital Expenditures Growth for Adc Therapeutics Sa's Suppliers
Capital Expenditures Growth for ADCT's Customers

You may also want to know
ADCT's Annual Growth Rates ADCT's Profitability Ratios ADCT's Asset Turnover Ratio ADCT's Dividend Growth
ADCT's Roe ADCT's Valuation Ratios ADCT's Financial Strength Ratios ADCT's Dividend Payout Ratio
ADCT's Roa ADCT's Inventory Turnover Ratio ADCT's Growth Rates ADCT's Dividend Comparisons



Companies with similar Capital Expenditures no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Stereotaxis Inc -0.81%$ -0.813 millions
Icon Plc-1.03%$ -1.033 millions
Alpine Immune Sciences Inc -1.72%$ -1.724 millions
Argenx se-2.99%$ -2.987 millions
Abbvie inc -3.76%$ -3.756 millions
Vanda Pharmaceuticals Inc -3.80%$ -3.802 millions
Warby Parker Inc -4.52%$ -4.516 millions
Bristol myers Squibb Company-4.62%$ -4.624 millions
Baxter International Inc -5.00%$ -5.000 millions
Progyny Inc -5.55%$ -5.548 millions
Koru Medical Systems Inc-6.92%$ -6.916 millions
Ufp Technologies Inc -7.02%$ -7.018 millions
Bio rad Laboratories Inc -7.27%$ -7.272 millions
Endo International Plc-8.13%$ -8.130 millions
Eterna Therapeutics Inc -9.52%$ -9.524 millions
Sotera Health Company-9.63%$ -9.633 millions
Hutchmed china Limited-11.05%$ -11.052 millions
Petvivo Holdings Inc-11.46%$ -11.461 millions
Novartis Ag-11.52%$ -11.519 millions
Charles River Laboratories International inc -12.02%$ -12.020 millions
Surgery Partners Inc -12.78%$ -12.775 millions
Xbiotech Inc -12.88%$ -12.879 millions
Conmed Corporation-14.46%$ -14.464 millions
Msa Safety Incorporated-14.60%$ -14.601 millions
Teva Pharmaceutical Industries Limited-16.20%$ -16.197 millions
Genedx Holdings Corp -16.28%$ -16.279 millions
Dexcom Inc -17.32%$ -17.323 millions
Davita Inc -17.74%$ -17.739 millions
Voyager Therapeutics Inc -19.08%$ -19.078 millions
Natera inc -19.40%$ -19.405 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com